With about $600 million in cash and short-term investments sitting on its balance sheet, ViroPharma
For $443 million up front (part of that in ViroPharma stock), ViroPharma is getting access to Lev's ultra-orphan disease drug Cinryze. The company is awaiting an FDA decision on marketing it as a treatment to prevent flare-ups of a very rare genetic inflammatory disorder.
It's estimated that the disorder, hereditary angioedema (HAE), affects around 10,000 people in the U.S., although only 4,600 patients have been diagnosed with it. Lev had received a rejection letter for Cinryze in January after the FDA asked for "additional analyses of existing efficacy data" and some more manufacturing data on the drug. Lev has tried to resolve the FDA's concerns, and another FDA marketing decision is expected on or around Oct. 14.
ViroPharma thinks Cinryze could be the first approved drug in the U.S. to help with HAE. There are similar competitors in late-stage clinical testing, like Dyax's
ViroPharma expects Cinryze to have a "comparable price to other ultra-orphan drugs," which would make the drug's annualized cost somewhere in the $200,000 to $400,000 range. If it's used by a quarter of the 4,600 identified HAE patients and is priced at $300,000 annually, then it could bring nearly $350 million into ViroPharma's coffers in relatively short order … unless Dyax and others come onto the market and drive the price down.
Many specialty pharmas similar to ViroPharma have been saving up large chunks of cash to make what is hoped to be a transformational acquisition. Not even counting the large-cap drugmakers like Novartis that are addicted to acquisitions, it's likely that those like BioMarin
ViroPharma acquired its only marketed drug, Vancocin, after it bought it from Eli Lilly
Some more biotech Foolishness:
More from The Motley Fool
Twitter Stock Upgraded: What You Need to Know
2018 could be the year Twitter turns profitable -- and Wall Street is getting excited.
Why RH Stock Rocketed 181% Higher Last Year
The upscale home furnishings retailer soared as management's strategy shift started to pay off.
This 11% Yielder Just Became a Bit Less Risky
Energy Transfer Partners LP is about to get a big cash windfall to pay down debt.